Page last updated: 2024-11-12

vtx-2337

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID16049404
CHEMBL ID3301618
SCHEMBL ID254984
MeSH IDM0575817

Synonyms (43)

Synonym
wp6py72zh3 ,
motolimod
vtx-378
unii-wp6py72zh3
vtx 2337
motolimod [usan:inn]
3h-1-benzazepine-4-carboxamide, 2-amino-n,n-dipropyl-8-(4-(1-pyrrolidinylcarbonyl)phenyl)-
926927-61-9
vtx-2337
motolimod [usan]
motolimod [who-dd]
motolimod [inn]
S7161
SCHEMBL254984
CHEMBL3301618
D10716
motolimod (usan/inn)
AKOS025289797
AC-32660
HY-13773
2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide
gtpl9026
2-amino-n,n-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3h-1-benzazepine-4-carboxamide
DTXSID10239107
EX-A1102
mfcd28044318
AS-74258
motolimod (vtx-2337)
DB12303
BCP16667
bdbm50559854
(1e,4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide
Q27087722
2-amino-n,n-dipropyl-8-[4-(1-pyrrolidinylcarbonyl)phenyl]-3h-1-benzazepine-4-carboxamide
SB16930
CCG-269323
A857320
2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide;motolimod
nsc777447
nsc-777447
BMB92761
SY122070
2-amino-n,n-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3h-benzo[b]azepine-4-carboxamide

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" In this study, a novel and sensitive liquid chromatography-tandem mass spectrometry method was developed for quantifying motolimod in rat plasma and subsequently used in a pharmacokinetic study."( Determination of motolimod concentration in rat plasma by liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study.
Choi, HI; Jeong, JW; Ji, YG; Koo, TS; Lee, JH; Lee, KR; Lee, SW; Shin, YM, 2020
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" Altogether, VTX-2337 remains promising as an adjuvant for cetuximab-based therapy however patients with high TLR8 expression may be more likely to derive benefit from this drug combination compared to patients with low TLR8 expression."( The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent.
Borcherding, N; Chan, CHF; Cheng, Y; Choi, AB; Gibson-Corley, KN; Lemke-Miltner, CD; Ogunsakin, A; Rajan, A; Salem, AK; Simons, AL; Weiner, GJ; Wongpattaraworakul, W, 2021
)
1.24
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Toll-like receptor 8Homo sapiens (human)EC50 (µMol)1.30000.48004.26369.0000AID1720360
Toll-like receptor 7Homo sapiens (human)EC50 (µMol)30.00000.00721.57446.8000AID1720361
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (29)

Processvia Protein(s)Taxonomy
regulation of protein phosphorylationToll-like receptor 8Homo sapiens (human)
inflammatory responseToll-like receptor 8Homo sapiens (human)
response to virusToll-like receptor 8Homo sapiens (human)
immunoglobulin mediated immune responseToll-like receptor 8Homo sapiens (human)
negative regulation of interleukin-12 productionToll-like receptor 8Homo sapiens (human)
positive regulation of interferon-alpha productionToll-like receptor 8Homo sapiens (human)
positive regulation of interferon-beta productionToll-like receptor 8Homo sapiens (human)
positive regulation of type II interferon productionToll-like receptor 8Homo sapiens (human)
positive regulation of interleukin-1 beta productionToll-like receptor 8Homo sapiens (human)
positive regulation of interleukin-6 productionToll-like receptor 8Homo sapiens (human)
positive regulation of interleukin-8 productionToll-like receptor 8Homo sapiens (human)
toll-like receptor 8 signaling pathwayToll-like receptor 8Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionToll-like receptor 8Homo sapiens (human)
innate immune responseToll-like receptor 8Homo sapiens (human)
positive regulation of innate immune responseToll-like receptor 8Homo sapiens (human)
defense response to virusToll-like receptor 8Homo sapiens (human)
cellular response to mechanical stimulusToll-like receptor 8Homo sapiens (human)
toll-like receptor signaling pathwayToll-like receptor 8Homo sapiens (human)
canonical NF-kappaB signal transductionToll-like receptor 8Homo sapiens (human)
regulation of protein phosphorylationToll-like receptor 7Homo sapiens (human)
inflammatory responseToll-like receptor 7Homo sapiens (human)
canonical NF-kappaB signal transductionToll-like receptor 7Homo sapiens (human)
I-kappaB phosphorylationToll-like receptor 7Homo sapiens (human)
JNK cascadeToll-like receptor 7Homo sapiens (human)
positive regulation of chemokine productionToll-like receptor 7Homo sapiens (human)
positive regulation of interferon-alpha productionToll-like receptor 7Homo sapiens (human)
positive regulation of interferon-beta productionToll-like receptor 7Homo sapiens (human)
positive regulation of type II interferon productionToll-like receptor 7Homo sapiens (human)
positive regulation of interleukin-8 productionToll-like receptor 7Homo sapiens (human)
toll-like receptor 7 signaling pathwayToll-like receptor 7Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionToll-like receptor 7Homo sapiens (human)
innate immune responseToll-like receptor 7Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIToll-like receptor 7Homo sapiens (human)
positive regulation of inflammatory responseToll-like receptor 7Homo sapiens (human)
defense response to virusToll-like receptor 7Homo sapiens (human)
positive regulation of macrophage cytokine productionToll-like receptor 7Homo sapiens (human)
response to cGMPToll-like receptor 7Homo sapiens (human)
cellular response to mechanical stimulusToll-like receptor 7Homo sapiens (human)
cellular response to virusToll-like receptor 7Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionToll-like receptor 7Homo sapiens (human)
toll-like receptor signaling pathwayToll-like receptor 7Homo sapiens (human)
positive regulation of interleukin-6 productionToll-like receptor 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
DNA bindingToll-like receptor 8Homo sapiens (human)
RNA bindingToll-like receptor 8Homo sapiens (human)
double-stranded RNA bindingToll-like receptor 8Homo sapiens (human)
single-stranded RNA bindingToll-like receptor 8Homo sapiens (human)
signaling receptor activityToll-like receptor 8Homo sapiens (human)
pattern recognition receptor activityToll-like receptor 8Homo sapiens (human)
double-stranded RNA bindingToll-like receptor 7Homo sapiens (human)
single-stranded RNA bindingToll-like receptor 7Homo sapiens (human)
protein bindingToll-like receptor 7Homo sapiens (human)
siRNA bindingToll-like receptor 7Homo sapiens (human)
pattern recognition receptor activityToll-like receptor 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
Golgi membraneToll-like receptor 8Homo sapiens (human)
endoplasmic reticulum membraneToll-like receptor 8Homo sapiens (human)
external side of plasma membraneToll-like receptor 8Homo sapiens (human)
endosome membraneToll-like receptor 8Homo sapiens (human)
endolysosome membraneToll-like receptor 8Homo sapiens (human)
plasma membraneToll-like receptor 8Homo sapiens (human)
Golgi membraneToll-like receptor 7Homo sapiens (human)
cytoplasmToll-like receptor 7Homo sapiens (human)
lysosomeToll-like receptor 7Homo sapiens (human)
endosomeToll-like receptor 7Homo sapiens (human)
endoplasmic reticulumToll-like receptor 7Homo sapiens (human)
endoplasmic reticulum membraneToll-like receptor 7Homo sapiens (human)
plasma membraneToll-like receptor 7Homo sapiens (human)
endosome membraneToll-like receptor 7Homo sapiens (human)
early phagosomeToll-like receptor 7Homo sapiens (human)
endolysosome membraneToll-like receptor 7Homo sapiens (human)
receptor complexToll-like receptor 7Homo sapiens (human)
plasma membraneToll-like receptor 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1720360Agonist activity at TLR8 in human cryopreserved PBMC assessed as inhibition of IL-12p40 production measured after 24 hrs2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.
AID1720361Agonist activity at TLR7 in human cryopreserved PBMC assessed as induction of IFNalpha production measured after 24 hrs2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1345474Human TLR8 (Toll-like receptor family)2012Clinical cancer research : an official journal of the American Association for Cancer Research, Jan-15, Volume: 18, Issue:2
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (57.14)24.3611
2020's6 (42.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.16 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index22.84 (26.88)
Search Engine Supply Index2.20 (0.95)

This Compound (24.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (28.57%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]